Profit180

19-Apr-2024 8:58 AM

Why Is BioNexus Gene Lab (BGLC) Stock Down 27% Today?

BioNexus Gene Lab (NASDAQ: BGLC ) stock is falling on Friday but investors will note that this comes after its shares underwent a rally late on Thursday. BioNexus Gene Lab shares closed out Thursday up 28.8% with about 3.1 million units traded.

18-Apr-2024 2:52 PM

BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare

KUALA LUMPUR, Malaysia, April 19, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corporation (NASDAQ: BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company. This investment underscores BGLC's commitment to advancing healthcare solutions through cutting-edge AI and predictive analytics.

13-Feb-2024 11:14 AM

Why Is BioNexus (BGLC) Stock Up 323% Today?

BioNexus (NASDAQ: BGLC ) stock is rocketing higher on Tuesday despite a lack of news concerning the chemical raw material products company. Instead, traders are seeing shares of BGLC stock rally this morning alongside heavy trading.

23-Aug-2023 7:53 AM

Why Is BioNexus Gene Lab (BGLC) Stock Up 33% Today?

BioNexus Gene Lab (NASDAQ: BGLC ) stock is rising higher on Wednesday despite a lack of news concerning the chemical raw material company. There haven't been any new press releases that explain why BGLC stock is up today.

24-Jul-2023 11:30 AM

BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market

KUALA LUMPUR, Malaysia, July 24, 2023 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BioNexus” or the “Company”) (Nasdaq: BGLC), an emerging company in the business of selling chemical raw materials in the Southeast Asia region and the development of safe, effective, and non-invasive liquid biopsy tests for early diagnosis and personalized health management, today announced the closing of an underwritten public offering (the “Offering”) of 1,437,500 shares of common stock, including 187,500 shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The Offering was priced at $4.00 per share for total gross proceeds of $5.75 million before deducting underwriting discounts and commissions and offering expense.

21-Jul-2023 7:40 AM

Why Is BioNexus Gene Lab (BGLC) Stock Up 64% Today?

BioNexus Gene Lab (NASDAQ: BGLC ) stock is taking off on Friday after the company uplisted its shares to the Nasdaq Capital Market. That saw the company's shares start trading on the Nasdaq Capital Market yesterday.

Symbol	BGLC
Market Cap	10.1M
Price	0.57
Open	0.56
52-wk High	9.49
50 Day Avg	0.65
Earnings Announcement	2024-05-14
Website	https://www.bionexusgenelab.com

Name	BioNexus Gene Lab Corp.
Shares Outstanding	17,667,700
Change %	0.3497%
Low	0.56
52-wk Low	0.08
200 Day Avg	0.74
Last Dividend	0.00

Exchange	NASDAQ
Volume	37,679
Previous Close	0.57
High	0.59
EPS	-0.18
PE	-3.19
Avg Volume	240,150
CUSIP	090628108

Description	BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Currency	USD
ISIN	US0906282076

Industry	Medical - Diagnostics & Research
Changes	0.00
CUSIP	090628108

BioNexus Gene Lab Corp. Outlook